Dr. Benjamin Kitchens, MD
What this data tells you about Dr. Kitchens
Dr. Benjamin Kitchens is a medical oncology specialist in Dallas, TX, with 12 years of NPI registration. Based on federal Medicare data, Dr. Kitchens performed 18,497 Medicare services across 1,167 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kitchens received a total of $93,373 from 58 pharmaceutical and/or device companies across 363 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kitchens is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 6,000 | $43 | $136 |
| Anti-nausea injection (fosaprepitant) | 4,200 | $0 | $5 |
| Contrast dye for imaging (iodine-based) | 2,509 | $0 | $3 |
| Paclitaxel chemotherapy injection | 1,784 | $0 | $8 |
| Dexamethasone injection (steroid) | 775 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 370 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 370 | $1 | $114 |
| Office visit, established patient (30-39 min) | 368 | $93 | $368 |
| Comprehensive metabolic blood panel | 350 | $10 | $64 |
| Complete blood count (CBC) with differential | 306 | $8 | $36 |
| Blood draw (venipuncture) | 277 | $8 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 129 | $22 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 112 | $103 | $707 |
| Carcinoembryonic antigen (cea) protein level | 93 | $18 | $99 |
| Injection, fluorouracil, 500 mg | 91 | $2 | $13 |
| Injection of additional new drug or substance into vein | 90 | $12 | $108 |
| Hospital follow-up visit, high complexity | 80 | $93 | $357 |
| Injection, carboplatin, 50 mg | 80 | $2 | $300 |
| Injection, zoledronic acid, 1 mg | 68 | $7 | $431 |
| Microscopic examination for white blood cells with manual cell count | 44 | $4 | $22 |
| Complete blood count (CBC), automated | 44 | $6 | $34 |
| New patient office visit, complex (60-74 min) | 37 | $166 | $709 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 30 | $48 | $313 |
| Office visit, established patient, complex (40-54 min) | 30 | $127 | $496 |
| Magnesium level test | 27 | $7 | $29 |
| Ct scan of chest with contrast | 25 | $51 | $821 |
| Administration of additional new drug or substance into vein, 1 hour or less | 24 | $52 | $344 |
| Injection, diphenhydramine hcl, up to 50 mg | 23 | $1 | $7 |
| CT scan of abdomen and pelvis with contrast | 20 | $163 | $1,067 |
| Unclassified drugs | 19 | $1 | $8 |
| Irrigation of implanted venous access drug delivery device | 15 | $19 | $114 |
| Initial hospital admission, high complexity | 15 | $136 | $694 |
| Infusion, normal saline solution , 1000 cc | 15 | $2 | $19 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 14 | $1,182 | $4,802 |
| Drug injection, under skin or into muscle | 14 | $11 | $96 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $54 | $211 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 12 | $14 | $94 |
| Administration of chemotherapy into vein using push technique | 12 | $81 | $500 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 12 | $90 | $657 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (74%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kitchens is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 15% of TX peers.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kitchens experienced with pembrolizumab injection (keytruda)?
Does Dr. Kitchens receive payments from pharmaceutical companies?
How do Dr. Kitchens's costs compare to other medical oncologists in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology